EpiPen patent expiry opens new era for innovation. The expiration of Viatris’s EpiPen patent in September 2025 will likely result in increased competition and lower costs in the epinephrine delivery space.

Boehringer and Click seek schizophrenia PDT approval after Phase III success. CT-155 significantly reduced negative symptoms associated with schizophrenia when used with antipsychotics.

Zimmer Biomet raises 2025 outlook amid strong portfolio growth. Since acquiring Paragon 28 in July, Zimmer revealed that sports medicine, extremities, trauma, craniomaxillofacial and thoracic (S.E.T) is now its second largest business.

Natera introduces prenatal test for detecting inherited conditions. The introduction of the test is underpinned by data from the blinded, prospective EXPAND study, which began in 2023.

HistoSonics announces acquisition by investor consortium for $2.25bn. The company will continue under the leadership of CEO and president Mike Blue, alongside his executive team.

Apreo Health raises $130m to fund emphysema implant pivotal trial. Beyond supporting a pivotal trial for Apreo’s BREATHE airway scaffold, the funds will support activities to demonstrate the implant’s market potential.

FTC files lawsuit to halt Edwards acquisition of JenaValve. The FTC asserts that Edwards acquisition of JenaValve, given it now owns rival TAVR-AR firm JC Medical, will eliminate competition in the US artificial heart valve market.

China NMPA approves Bracco Imaging's contrast agent for infertility diagnosis. The diagnostic performance of HyCoSy with SF6 microbubbles claims to have been validated by a meta-analysis of 24 trials.

Inside Dexcom’s strategy to stay ahead in the $13.6bn CGM market. With a new CEO taking over in 2026, Dexcom aims to stay ahead of its CGM competitors through a combination of innovation and product market expansion.

Exact Sciences to acquire US rights for Freenome's blood-based CRC test. Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November.

HeartFlow sets sights on $300m IPO. HeartFlow joins a group of medtechs planning to go public in 2025, including Medtronic’s new standalone diabetes business and AI spinal surgery company Carlsmed.

MedTech Europe renews call for zero-tariff deal as Trump imposes 15% levy on EU. MedTech Europe remains “deeply concerned” about how the 15% tariffs on the EU could impact patient care and innovation.

Microbot Medical secures grant for endovascular robotic system. IIA recognises Microbot’s recent milestones and the potential impact of the Liberty system.

Respiree secures FDA 510(k) extension for cardio-respiratory wearable. The RS001 chest-worn device directly measures respiration and provides passive cardio-respiratory monitoring.

Podcast: Key market trends in medical devices and the materials driving progress. A key trend in the medical device market is smaller and smarter, which requires advanced materials and is the focus of the latest podcast from Alleima Medical.

Absence of human touch makes AI an inadequate therapy substitute. Myriad factors are leading to an increased reliance on AI chatbots for mental health support, but the technology’s shortcomings must be remembered.

Alcon strikes $1.5bn deal to acquire ailing rival STAAR Surgical. Alcon’s purchase of STAAR Surgical is the latest move in a year marked by strategic expansion through acquisitions.

BD announces $35m investment to expand prefilled syringe manufacturing in US. The syringes are said to be produced using a hands-free and fully automated process to minimise contamination risks.

FDA grants conditional approval for TransMedics’ OCS ENHANCE Heart trial. The anticipated sample size for both parts of the trial is set to exceed 650 subjects.

Establishment Labs, led by founder Juan José Chacón-Quiros, is making strides in the field of breast aesthetics and reconstruction, emphasizing patient safety and minimally invasive solutions. Read more -